docetaxel anhydrous has been researched along with Thrombotic Microangiopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abramson, VG; Beckermann, KE; Iams, W; Mayer, IA; Neff, AT | 1 |
| Siau, K; Varughese, M | 1 |
2 other study(ies) available for docetaxel anhydrous and Thrombotic Microangiopathies
| Article | Year |
|---|---|
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Receptor, ErbB-2; Taxoids; Thrombotic Microangiopathies; Trastuzumab | 2013 |
Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids; Thrombotic Microangiopathies; Trastuzumab; Treatment Outcome | 2010 |